Skip to main content
All lobbying filings

EAST END GROUP, LLC

Lobbying for ALVOGEN · Pharmaceutical company developing and manufacturing generic, brand and biosimilar products

 Filing 4th Quarter - Report
4th Quarter (Oct 1 - Dec 31) 2025 · New Jersey · House · Senate · $45,000.00 income · posted Jan 20, 2026

Official filing document

 Lobbying activity 3
Health Issues

Funding for pandemic influenza antivirals in the LHHS Appropriations bill. Regulatory and legislative issues related to development and procurement of pandemic influenza antivirals. Issues related to domestic manufacturing and on-shoring pharmaceuticals.

Tariff (miscellaneous tariff bills)

Section 232 investigation into pharmaceuticals and unfair trade practices.

Manufacturing

Buy America legislation, 232 tariff investigation, regulatory incentives for domestic manufacturing.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem